bioRxivCell Biology
Entrectinib - a SARS-CoV-2 inhibitor in Human Lung Tissue (HLT) cells
A. Peralta-Garcia, M. Torrens-Fontanals, T. M. Stepniewski, J. Grau-Exposito, D. Perea, V. Ayinampudi, M. Waldhoer, M. Zimmermann, M. J. Buzon, M. Genesca, J. Selent
Abstract
Since the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify potential drug candidates that are able to block the entrance of the virus into human cells. By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, we identify entrectinib as a promising antiviral drug. We found that part of the antiviral action of entrectinib is mediated by a non-specific mechanism, likely occurring at the viral membrane level. Such a profile could provide entrectinib with protection against the development of drug resistance by emerging SARS-CoV-2 variants.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: deep learning
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells
X. Nguyenla, E. Wehri, … J. Schaletzky·bioRxiv·Sep 18, 2020
- Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
D. F. Sales-Medina, L. R. P. Ferreira, … L. Freitas Junior·bioRxiv·Jul 9, 2020
- Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2
M. Dittmar, J. S. Lee, … S. Cherry·bioRxiv·Jun 19, 2020
- Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models
- Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.
N. Yamamoto, S. Matsuyama, … N. Yamamoto·bioRxiv·Apr 6, 2020
- Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate